[go: up one dir, main page]

WO2014140680A8 - Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection - Google Patents

Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection Download PDF

Info

Publication number
WO2014140680A8
WO2014140680A8 PCT/IB2013/001634 IB2013001634W WO2014140680A8 WO 2014140680 A8 WO2014140680 A8 WO 2014140680A8 IB 2013001634 W IB2013001634 W IB 2013001634W WO 2014140680 A8 WO2014140680 A8 WO 2014140680A8
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
celgosivir
virus infection
dosing regimen
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/001634
Other languages
French (fr)
Other versions
WO2014140680A1 (en
Inventor
Subhash Vasudevan
Abhay RATHORE
Cynthia Sung
Satoru Watanabe
Jenny LOW
Eng Eong Ooi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Singapore Health Services Pte Ltd
Original Assignee
National University of Singapore
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore, Singapore Health Services Pte Ltd filed Critical National University of Singapore
Publication of WO2014140680A1 publication Critical patent/WO2014140680A1/en
Publication of WO2014140680A8 publication Critical patent/WO2014140680A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within 48 to 72 hours of fever onset due to dengue infection and then every.6 to 1-2-hours until there is an improvement in the infection. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.
PCT/IB2013/001634 2013-03-15 2013-07-26 Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection Ceased WO2014140680A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798100P 2013-03-15 2013-03-15
US61/798,100 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014140680A1 WO2014140680A1 (en) 2014-09-18
WO2014140680A8 true WO2014140680A8 (en) 2015-06-25

Family

ID=51535932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/001634 Ceased WO2014140680A1 (en) 2013-03-15 2013-07-26 Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection

Country Status (2)

Country Link
AU (1) AU2013203400B2 (en)
WO (1) WO2014140680A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119546301A (en) * 2022-07-05 2025-02-28 60度制药有限责任公司 Method for treating respiratory tract infection using castanospermine analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501352D0 (en) * 2005-01-21 2005-03-02 Slingsby Jason H Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope

Also Published As

Publication number Publication date
WO2014140680A1 (en) 2014-09-18
AU2013203400B2 (en) 2016-01-21
AU2013203400A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
MY180145A (en) Cenicriviroc compositions and methods of making and using the same
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA202090258A3 (en) PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
PH12019550113A1 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EA201590457A1 (en) SULFAMOIL-Arylamides and Their Use as Medicinal Products for the Treatment of Hepatitis B
EA201590343A1 (en) ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
SI2709613T1 (en) Methods for treating hcv
MX2016004492A (en) Inhibitors of human immunodeficiency virus replication.
EA201791872A1 (en) POLYCYCLIC CARBAMOILPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS
MY194294A (en) Novel viral replication inhibitors
MX2020011107A (en) Glycosidase regimen for treatment of infectious disease.
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
EA201592242A1 (en) PYRIDON DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
RU2014117294A (en) 4,6-DI (3,12-DIAZA-6,9-DIAZONIADISPIRO [5.2.5.2] HEXADECAN-1-IL) -2-METHYL-5-NITROPYRIMIDINE TETRACHLORIDE DIHYDROCHLORIDE HEXAHYDRATE FOR THE TREATMENT OF CHEMISE
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
BR112017018977A2 (en) a compound, pharmaceutical composition, methods for treating a hepatitis c infection or a condition resulting from a hepatitis c infection in a host in need thereof and for manufacturing a medicament directed for therapeutic use for treating a virus infection of hepatitis c, use of a compound, and pharmaceutical formulation ?.
UA90646C2 (en) treatment OF often RECCURENT chronic herpetic infection caused by herpes virus of simple I and II type

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13877612

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13877612

Country of ref document: EP

Kind code of ref document: A1